STOCKHOLM Meda on Monday announced an agreement to acquire the specialty pharmaceutical company Alaven in a move that will “significantly enhance Meda’s marketing capabilities in the United States and expand the therapeutic focus to include both gastroenterology and women’s health — areas that Meda already operates in outside of the United States,” the company stated.
Meda also identified Alaven’s over-the-counter platform, which accounts for approximately 25% of Alaven’s sales, as an attractive element to the deal.
